GTPase KRas — Drug Target

All drugs that target GTPase KRas — marketed and clinical-stage.

Marketed (2)

• Lumakras · Amgen · Oncology
  Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth.
• Krazati · Bristol-Myers Squibb · Oncology
  Krazati works by binding to and inhibiting the GTPase activity of the KRAS G12C protein, preventing it from sending signals that promote cancer cell growth.